Literature DB >> 17853625

Treatment options for insomnia.

Kalyanakrishnan Ramakrishnan1, Dewey C Scheid.   

Abstract

The frequency of sleep disruption and the degree to which insomnia significantly affects daytime function determine the need for evaluation and treatment. Physicians may initiate treatment of insomnia at an initial visit; for patients with a clear acute stressor such as grief, no further evaluation may be indicated. However, if insomnia is severe or long-lasting, a thorough evaluation to uncover coexisting medical, neurologic, or psychiatric illness is warranted. Treatment should begin with nonpharmacologic therapy, addressing sleep hygiene issues and exercise. There is good evidence supporting the effectiveness of cognitive behavior therapy. Exercise improves sleep as effectively as benzodiazepines in some studies and, given its other health benefits, is recommended for patients with insomnia. Hypnotics generally should be prescribed for short periods only, with the frequency and duration of use customized to each patient's circumstances. Routine use of over-the-counter drugs containing antihistamines should be discouraged. Alcohol has the potential for abuse and should not be used as a sleep aid. Opiates are valuable in pain-associated insomnia. Benzodiazepines are most useful for short-term treatment; however, long-term use may lead to adverse effects and withdrawal phenomena. The better safety profile of the newer-generation nonbenzodiazepines (i.e., zolpidem, zaleplon, eszopidone, and ramelteon) makes them better first-line choices for long-term treatment of chronic insomnia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17853625

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  21 in total

1.  Sleep physiology, abnormal States, and therapeutic interventions.

Authors:  Alvah T Wickboldt; Alex F Bowen; Aaron J Kaye; Adam M Kaye; Franklin Rivera Bueno; Alan D Kaye
Journal:  Ochsner J       Date:  2012

2.  Sleep Health and Appropriate Use of OTC Sleep Aids in Older Adults-Recommendations of a Gerontological Society of America Workgroup.

Authors:  Steven M Albert; Thomas Roth; Michael Toscani; Michael V Vitiello; Phyllis Zee
Journal:  Gerontologist       Date:  2015-10-28

3.  Pharmacological Treatment of Insomnia.

Authors:  Janette D Lie; Kristie N Tu; Diana D Shen; Bonnie M Wong
Journal:  P T       Date:  2015-11

4.  Sleep-inducing effect of lettuce (Lactuca sativa) varieties on pentobarbital-induced sleep.

Authors:  Hae Dun Kim; Ki-Bae Hong; Dong Ouk Noh; Hyung Joo Suh
Journal:  Food Sci Biotechnol       Date:  2017-05-29       Impact factor: 2.391

5. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

6.  Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats.

Authors:  Max P Huang; Kushan Radadia; Brian W Macone; Sanford H Auerbach; Subimal Datta
Journal:  Behav Brain Res       Date:  2010-02-12       Impact factor: 3.332

7.  A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer.

Authors:  Doris Howell; Thomas K Oliver; Sue Keller-Olaman; Judith Davidson; Sheila Garland; Charles Samuels; Josée Savard; Cheryl Harris; Michèle Aubin; Karin Olson; Jonathan Sussman; James Macfarlane; Claudette Taylor
Journal:  Support Care Cancer       Date:  2013-05-25       Impact factor: 3.603

8.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

9.  Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

Authors:  Susan M Hanson; Elaine V Morlock; Kenneth A Satyshur; Cynthia Czajkowski
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

Review 10.  Ramelteon: a review of its use in insomnia.

Authors:  Dene Simpson; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.